At Pittcon 2009, Bruker Corporation
(NASDAQ: BRKR) launches numerous new scientific and analytical products
and solutions. The new systems and solutions introduced today are focused on
bringing more productivity and specificity to confident routine analysis, and
on opening new horizons for advanced research applications.
New D2 PHASER Benchtop X-ray Diffraction (XRD) System for Crystalline Phase Analysis (Graphic: Business Wire)
Bruker is announcing several new solutions-oriented, turn-key, push-button
analyzers based on X-ray analysis, on infrared and NMR molecular spectroscopy,
and on mass spectrometry. Bruker is leveraging its high-performance technologies
into new, more compact, easier to use, faster, more sensitive and more specific
analytical solutions that address large pharma/biotech, applied and industrial
markets. Applications range from biologics quality control (QC), to on-line
pharma process analytical technologies (PAT) tablet characterization, to food
and feed analysis, to elemental analysis in forensics, precious metals and cement,
to positive materials identification (PMI) in the power and aerospace industries.
At the same time, Bruker is introducing cutting-edge, truly innovative and
completely unique new research capabilities that will enable scientists to open
up new scientific frontiers in membrane protein research and in applied proteomics.
The new products and solutions launched by Bruker at Pittcon 2009 include:
X-Ray Materials Research and Elemental Analysis
- D2 PHASER™: Bruker enters the benchtop X-ray diffraction (XRD) market
with a compact, high-performance XRD spectrometer for the qualitative and
quantitative analysis of crystalline phases.
- S8 LION™: Bruker enters the simultaneous wavelength dispersive X-ray
Fluorescence (WDXRF) market with a high-end, next-generation spectrometer
for process and quality control in cement, minerals and mining.
- M1 ORA™ and M4 TORNADO™: Bruker extends its product portfolio
for the micro X-Ray Fluorescence (µ-XRF) market with a convenient, small
precious metals and jewelry analyzer, as well as a high-end, automated, vacuum
micro-XRF spectrometer for non-destructive, elemental microanalysis on solid
or liquid samples, particles, inclusions and coatings with unprecedented speed
and accuracy for a wide range of applications, including microelectronics,
RoHS, forensics and geology.
- S1 SORTER & S1 TURBOSD: Bruker broadens its handheld XRF product line
with a fast, affordable alloy sorter, and a next-generation SDD-based high-performance
handheld XRF for the most demanding applications and light-element analysis.
- Q8 MAGELLAN™: This new version of Bruker’s successful, high-end
Q8 spark-OES series provides even better performance, long-term stability,
convenience and ease-of-use for the most demanding metallurgical applications.
- 263 GHz Avance™ Solid-State DNP-NMR spectrometer: Bruker pioneers
the world’s first commercially available solid-state DNP-NMR system
that opens up new possibilities for scientific research in the fields of biological
solids and nano-materials, particularly in membrane proteins. DNP-NMR can
provide signal enhancement factors of 50x or higher.
- TANDEM™ and LANCIR™: Bruker expands its market leadership in
pharmaceutical Process Analytical Technology (PAT) with next-generation near
infrared (NIR) on-line PAT analyzers for blend uniformity and tablet characterization.
Life-Science Mass Spectrometry
- EdmassTM Micro: Bruker leverages its leadership in research proteomics into
the new field of ‘applied proteomics’ with the introduction of
its revolutionary, top-down Edmass protein sequencing solution for all molecular
biologists without mass spectrometry expertise, as well as for biologics QC
in pharma, biotech and CRO companies. The Edmass Micro Solution is based on
convenient bench-top MALDI-TOF mass spectrometry that fragments intact proteins
across a wide mass range and calls amino acid sequences of up to 80 residues,
all without prior protein digestion. Sequence confirmation of purified or
recombinant proteins takes just a few minutes and requires essentially no
- Edmass™ Ultra: This high-end Edmass solution is based on high-performance
MALDI-TOF/TOF technology and in addition delivers and applies Bruker’s
unique T3-Sequencing™ technology to provide protein N- and C-terminal
sequence information, even on N-term modified (blocked) proteins, thereby
overcoming many of the previous limitations of now discontinued Edman sequencing
Frank Laukien, Ph.D., Bruker’s President and CEO, commented: "We
are very pleased to unveil so many innovative systems and solutions at Pittcon
this year, and believe that our new products will further enhance our position
in the market, offering exceptionally powerful and convenient capabilities to
our customers. Particularly, our Bruker AXS Materials Research and Elemental
Analysis businesses have introduced numerous new products that had been under
development in some cases for several years, and which now leverage our industry-leading
technology portfolio across a much broader range of applications than ever before.
With our new product launches today, Bruker AXS has entered new market segments
in simultaneous WDXRF and micro-XRF, significantly increasing our addressable
Today, the Bruker BioSpin group is opening up a new page on solid-state NMR.
The dramatic signal enhancement factors that can be achieved with our new and
unique DNP-NMR system, enable researchers to study important membrane proteins
or dilute samples that had previously been inaccessible to NMR. Bruker BioSpin
today also announces its acquisition of PERCH Solutions Ltd., a Spectral Prediction
and Molecular Modeling Software company whose products Bruker has integrated
for small molecule structure verification and elucidation by NMR.”
Dr. Laukien continued: “The introduction of a faster, more powerful and
much more convenient next-generation protein sequencing technology, makes our
new Edmass solution an excellent example of the progress made in proteomics
research to where today we really are at the dawn of a new ‘applied proteomics’
age with convenient, new proteomics-derived products for all biologists, clinical
researchers, and in the future also for proteomics-based clinical routine applications